Mark Matijevic
Impact in
-
- Immunotherapy and Immune Responses
-
- Cervical Cancer and HPV Research
- Hepatitis B Virus Studies
Papers in
-
- DNA Repair Mechanisms 2
- Oncology 4
- PARP inhibition in cancer therapy 3
- Co-authors
- Robert G. Urban (3 shared papers)Mary Lynne Hedley (2 shared papers)Joel M. Palefsky (1 shared paper)Barbara Klencke (1 shared paper)Maria Da Costa (1 shared paper)Jennifer Wilson (1 shared paper)Michael J. Berry (1 shared paper)Naomi Jay (1 shared paper)
- Journals
- Journal of Clinical Oncology (5 papers)Alzheimer s & Dementia (3 papers)Molecular Cancer Therapeutics (1 paper)Arthritis & Rheumatology (1 paper)Blood (1 paper)
- Partner nations
- United StatesJapanUnited Kingdom
In The Last Decade
Mark Matijevic
19 papers receiving 479 citations
Peers
Comparison fields: 5 of 59
- Immunology 196
- Epidemiology 137
- Endocrinology, Diabetes and Metabolism 66
- Oncology 101
- Molecular Biology 157
Countries citing papers authored by Mark Matijevic
This map shows the geographic impact of Mark Matijevic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Matijevic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Matijevic more than expected).
Fields of papers citing papers by Mark Matijevic
This network shows the impact of papers produced by Mark Matijevic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Matijevic. The network helps show where Mark Matijevic may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Matijevic, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. | 2002 | 199 |
| 2 | 2017 | 66 | |
| 3 | 2020 | 60 | |
| 4 | 2011 | 44 | |
| 5 | 2023 | 37 | |
| 6 | 2013 | 20 | |
| 7 | 2012 | 19 | |
| 8 | 2012 | 14 | |
| 9 | 2012 | 9 | |
| 10 | 2015 | 7 | |
| 11 | 2011 | 5 | |
| 12 | 2005 | 4 | |
| 13 | 2014 | 4 | |
| 14 | 2018 | 3 | |
| 15 | 2014 | 3 | |
| 16 | 2024 | 2 | |
| 17 | 2015 | 2 | |
| 18 | 2025 | 1 | |
| 19 | 2015 | 1 | |
| 20 | 2024 | 0 |
About Mark Matijevic
Mark Matijevic is a scholar working on Molecular Biology, Oncology, Physiology, Immunology and Pharmacology, having authored 20 papers that have together received 500 indexed citations. Recurring topics across this work include Thyroid Cancer Diagnosis and Treatment (3 papers), PARP inhibition in cancer therapy (3 papers), Immunotherapy and Immune Responses (3 papers), DNA Repair Mechanisms (2 papers), Alzheimer's disease research and treatments (2 papers), Cholinesterase and Neurodegenerative Diseases (2 papers), Cervical Cancer and HPV Research (2 papers) and Systemic Lupus Erythematosus Research (2 papers). The work is most often cited by research in Immunology (196 citations), Epidemiology (137 citations), Endocrinology, Diabetes and Metabolism (66 citations), Oncology (101 citations) and Molecular Biology (157 citations). Mark Matijevic has collaborated with scholars based in United States, Japan and United Kingdom. Frequent co-authors include Robert G. Urban, Mary Lynne Hedley, Joel M. Palefsky, Barbara Klencke, Maria Da Costa, Jennifer Wilson, Michael J. Berry, Naomi Jay, Teresa M. Darragh and Janet L. Lathey. Their work appears in journals such as Journal of Clinical Oncology, Alzheimer s & Dementia, Molecular Cancer Therapeutics, Arthritis & Rheumatology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.